Posted by Michael Wonder on 12 Apr 2018
Health Canada accepts Mitsubishi Tanabe Pharma Corporation's NDS filing for edaravone to treat ALS, grants priority review
9 April 2018 - Mitsubishi Tanabe Pharma Canada launched in Toronto to prepare business operations.
Mitsubishi Tanabe Pharma Corporation and Mitsubishi Tanabe Pharma America today announced that Health Canada has accepted MTPC's new drug submission for edaravone, an intravenous treatment option for amyotrophic lateral sclerosis (ALS), a rapidly progressive neurological disease.i Health Canada also informed the company that the NDS has been granted Priority Review.
In March of 2018, Mitsubishi Tanabe Pharma America established the subsidiary Mitsubishi Tanabe Pharma Canada to prepare the required infrastructure and business operations to facilitate the distribution of the drug in Canada, if and when approved by Health Canada.
